Clinical trial reveals positive results for treating children with rare gliomas
Tafinlar and Mekinist led to a 56% overall response rate in children with BM-HGG
Read More
Tag: Tafinlar
Novartis’ Tafinlar plus Mekinist shows long-term benefit in advanced melanoma
Over half of patients treated with combination therapy were alive and relapse-free after five years
Read More
Yescarta rejected among other SMC decisions
Gilead’s CAR-T therapy Yescarta has been rejected by the Scottish Medicines Consortium (SMC) for use on NHS Scotland, but Novartis’ Kymriah was given a green light.
Read More
NHS green light for Novartis skin cancer combo
The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available to eligible skin cancer patients, after cost regulators published guidance backing funds for the treatment.
Read More
NICE nod for Novartis’ targeted skin cancer combo
The National Institute for Health and Care Excellence has backed NHS funding for Novartis’ oral targeted adjuvant combination therapy Tafinlar and Mekinist, offering new hope to patients with a specific type of skin cancer.
Read More
Breakthrough badge for Novartis’ skin cancer combo
A targeted combination therapy being developed by Novartis as adjuvant treatment for patients with a certain type of melanoma has been assigned breakthrough designation in the US.
Read More
Green light for Novartis’ lung cancer combination therapy
Novartis’ combination therapy Tafinlar + Mekinist has won approval from the US Food and Drug Administration to treat patients with metastatic non-small cell lung cancer (NSCLC) carrying the BRAF V600E mutation.
Read More
EU OKs Novartis’ Tafinlar/Mekinist combo for lung cancer
European regulators have expanded the scope of Novartis’ Tafinlar/Mekinist combination to include the treatment of patients with a certain form of lung cancer.
Read More
SMC clears three new drugs for NHS Scotland use
Three new medicines have been endorsed for routine use on the NHS giving patients new options for skin cancer, chronic myeloid leukaemia, and anticoagulant reversal.
Read More
Five new medicines make it onto the NHS
NICE has published new guidelines endorsing NHS use of five medicines, widening treatment options for some patients with lung cancer, high cholesterol, melanoma and the skin condition hidradentitis.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
